{"id":"ebixa","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Disease of liver","Impaired renal function disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ebixa","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:23:12.640936+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:23:19.199692+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ebixa","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:23:20.045809+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glutamate [NMDA] receptor negative allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:20.631952+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1699/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:20.524921+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase"},"_scrapedAt":"2026-03-27T23:45:08.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:22.411713+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Moderate to Severe Alzheimer's Type Dementia","diseaseId":"moderate-to-severe-alzheimer's-type-dementia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07470606","phase":"PHASE2","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-03","conditions":"Brain Tumor","enrollment":108},{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT04966546","phase":"EARLY_PHASE1","title":"Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2022-06-01","conditions":"Chronic Subdural Hematoma","enrollment":""},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"Autism, Autism Spectrum Disorder, Nonverbal Learning Disability","enrollment":25},{"nctId":"NCT07248228","phase":"PHASE2","title":"Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-03","conditions":"Brain Metastases","enrollment":90},{"nctId":"NCT07417670","phase":"PHASE4","title":"Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Carnot Laboratories","startDate":"2024-10-04","conditions":"Alzheimer Disease","enrollment":105},{"nctId":"NCT03527472","phase":"PHASE2","title":"Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2018-08-23","conditions":"Lupus Erythematosus, Systemic","enrollment":111},{"nctId":"NCT04857983","phase":"PHASE2, PHASE3","title":"Memantine Augmentation of Targeted Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-07-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":62},{"nctId":"NCT07351773","phase":"NA","title":"Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease","status":"COMPLETED","sponsor":"Taizhou Second People's Hospital","startDate":"2025-01-26","conditions":"Alzheimer's Disease(AD), Cognitive Dysfunction","enrollment":40},{"nctId":"NCT05063851","phase":"PHASE2","title":"The Use of Memantine for Prevention of Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2021-10-11","conditions":"Alzheimer Disease","enrollment":32},{"nctId":"NCT04804644","phase":"PHASE3","title":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-10","conditions":"Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma","enrollment":200},{"nctId":"NCT03550391","phase":"PHASE3","title":"Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-11-22","conditions":"Brain Metastases","enrollment":206},{"nctId":"NCT03703856","phase":"PHASE4","title":"Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2019-01-31","conditions":"Alzheimer Disease","enrollment":53},{"nctId":"NCT05418049","phase":"PHASE2","title":"Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-09-08","conditions":"Fragile X Syndrome","enrollment":45},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":"Central Nervous System Carcinoma","enrollment":192},{"nctId":"NCT02144584","phase":"EARLY_PHASE1","title":"Memantine for Enhanced Stroke Recovery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-01","conditions":"Ischemic Stroke, Upper Extremity Weakness","enrollment":20},{"nctId":"NCT07251023","phase":"PHASE3","title":"Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia","status":"RECRUITING","sponsor":"Bigespas LTD","startDate":"2025-11-20","conditions":"Alzheimer Type Dementia","enrollment":450},{"nctId":"NCT05013892","phase":"PHASE2","title":"NTS-WBRT in Brain Metastases","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-08","conditions":"Brain Metastases","enrollment":41},{"nctId":"NCT05796752","phase":"PHASE2, PHASE3","title":"Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2023-08-02","conditions":"Skin-Picking, Trichotillomania (Hair-Pulling Disorder)","enrollment":26},{"nctId":"NCT06501638","phase":"PHASE2","title":"Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats","status":"COMPLETED","sponsor":"Shanghai East Hospital","startDate":"2024-08-29","conditions":"Atrial Premature Beats, Contractions, or Systoles","enrollment":256},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT00262470","phase":"PHASE1, PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":"Tachycardia, Chronic Orthostatic Intolerance","enrollment":150},{"nctId":"NCT06789757","phase":"PHASE2","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-02-25","conditions":"Hepatocellular Carcinoma","enrollment":19},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT06007846","phase":"PHASE2, PHASE3","title":"A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2023-07-31","conditions":"Hepatocellular Carcinoma, Cirrhosis","enrollment":12},{"nctId":"NCT06041789","phase":"PHASE2","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-02-03","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT02466191","phase":"PHASE4","title":"Treatment of Pendular Nystagmus in OPT","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":"Pendular Nystagmus, Oculopalatal Tremor","enrollment":7},{"nctId":"NCT01744444","phase":"PHASE2","title":"Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2012-11","conditions":"Pendular Nystagmus Patients With Multiple Sclerosis","enrollment":10},{"nctId":"NCT01188525","phase":"PHASE1","title":"Pharmacokinetic Study to Characterize Individual Metabolic Profile","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2010-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT06727773","phase":"PHASE2","title":"Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-05-07","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment","enrollment":90},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT07094438","phase":"PHASE1","title":"Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Alzheimer Disease","enrollment":98},{"nctId":"NCT06862960","phase":"PHASE2","title":"Ozanimod in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"ChenXiaoChun","startDate":"2025-07-01","conditions":"Alzheimer Disease","enrollment":40},{"nctId":"NCT04588246","phase":"PHASE3","title":"Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery","status":"TERMINATED","sponsor":"NRG Oncology","startDate":"2021-08-05","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma","enrollment":19},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT01430351","phase":"PHASE1","title":"Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-09-14","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":144},{"nctId":"NCT05045950","phase":"PHASE2","title":"Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-17","conditions":"Brain Metastases","enrollment":53},{"nctId":"NCT02360215","phase":"PHASE3","title":"Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2015-07","conditions":"Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm","enrollment":518},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":"Neurocognitive Dysfunction","enrollment":101},{"nctId":"NCT06914310","phase":"PHASE2, PHASE3","title":"Memantine as an Additive Therapy in Patients With Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-03-25","conditions":"Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury (TBI)","enrollment":80},{"nctId":"NCT04117178","phase":"PHASE4","title":"Monitoring Anti-Dementia Drugs by Serum Levels","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2020-02-04","conditions":"Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease","enrollment":132},{"nctId":"NCT05801380","phase":"","title":"Monitoring Drug Efficacy in Patients with Alzheimer's Disease","status":"RECRUITING","sponsor":"University of the Philippines","startDate":"2022-02-14","conditions":"Alzheimer Disease","enrollment":60},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT04217694","phase":"EARLY_PHASE1","title":"Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-02-17","conditions":"Malignant Central Nervous System Neoplasm, Primary Central Nervous System Neoplasm","enrollment":18},{"nctId":"NCT06679387","phase":"PHASE2","title":"\"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients\"","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-30","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":80},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT04792645","phase":"PHASE2","title":"Memantine in Body Focused Repetitive Behaviors","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-06-15","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT06337994","phase":"PHASE3","title":"Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Treatment of Cognitive Deficits After Traumatic Brain Injury","enrollment":60},{"nctId":"NCT04538066","phase":"PHASE2","title":"Bryostatin Treatment of Moderately Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Neurotrope Bioscience, Inc.","startDate":"2020-08-30","conditions":"Alzheimer Disease","enrollment":122},{"nctId":"NCT01333865","phase":"PHASE4","title":"A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-01","conditions":"Autism Spectrum Disorders","enrollment":25},{"nctId":"NCT01972074","phase":"PHASE3","title":"Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02-17","conditions":"Autism Spectrum Disorder","enrollment":84},{"nctId":"NCT05664464","phase":"PHASE1, PHASE2","title":"Glutamate Inhibitors in Glioblastoma","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2023-01-01","conditions":"Glioblastoma","enrollment":120},{"nctId":"NCT04698525","phase":"PHASE3","title":"Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2019-02-15","conditions":"Migraine Headache","enrollment":33},{"nctId":"NCT03670095","phase":"PHASE1","title":"Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-08-28","conditions":"Healthy","enrollment":64},{"nctId":"NCT00401167","phase":"PHASE4","title":"Memantine for Agitation and Aggression in Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2006-11","conditions":"Alzheimer's Disease","enrollment":31},{"nctId":"NCT05647473","phase":"PHASE2","title":"Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-02-20","conditions":"Orthostatic Hypotension, Alzheimer Disease","enrollment":66},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT03194906","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-11-07","conditions":"Glioma of Brain, Craniopharyngioma, Ependymoma","enrollment":34},{"nctId":"NCT02304302","phase":"PHASE2","title":"Down Syndrome Memantine Follow-up Study","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-10","conditions":"Down Syndrome, Intellectual Disability","enrollment":160},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT05834231","phase":"PHASE1, PHASE2","title":"Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-08","conditions":"Cancer","enrollment":60},{"nctId":"NCT04033419","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-25","conditions":"Cognitive Decline, Chemo-brain","enrollment":55},{"nctId":"NCT05807165","phase":"","title":"HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Brain Oligometastases","enrollment":115},{"nctId":"NCT05804279","phase":"PHASE1","title":"Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults","status":"COMPLETED","sponsor":"Hyundai Pharm","startDate":"2022-12-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT03860597","phase":"PHASE4","title":"Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-04-01","conditions":"Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder","enrollment":42},{"nctId":"NCT00646204","phase":"PHASE4","title":"Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-04","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":"Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia","enrollment":89},{"nctId":"NCT01555697","phase":"PHASE1, PHASE2","title":"Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-07","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT05538507","phase":"PHASE2","title":"Efficacy of Chinese Traditional Medicine \"Smart Soup\" in Cognition and Behavior Regulation in Alzheimer's Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-06-01","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":180},{"nctId":"NCT05531383","phase":"NA","title":"Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Minia University","startDate":"2021-11-26","conditions":"Traumatic Brain Injury","enrollment":70},{"nctId":"NCT05532644","phase":"","title":"Correlation of P-glycoprotein Polymorphisms With Microbial Metabolites in Patients With Alzheimer's Disease on Medication","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-09","conditions":"Alzheimer Disease","enrollment":135},{"nctId":"NCT03986424","phase":"PHASE3","title":"Local Study of Akatinol Memantine in VaD in Russia","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2018-01-23","conditions":"Vascular Dementia","enrollment":130},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150},{"nctId":"NCT03954613","phase":"PHASE4","title":"Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2020-10-15","conditions":"Alzheimer Disease, Cognitive Change","enrollment":198},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","startDate":"2021-03-01","conditions":"Dementia","enrollment":16},{"nctId":"NCT00371059","phase":"PHASE4","title":"Memantine for Agitation in Dementia","status":"COMPLETED","sponsor":"East Kent Hospitals University NHS Foundation Trust","startDate":"2007-09","conditions":"DEMENTIA","enrollment":153},{"nctId":"NCT03709888","phase":"","title":"Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2016-07-09","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":20},{"nctId":"NCT03779672","phase":"PHASE4","title":"Memantine for Epileptic Encephalopathy","status":"COMPLETED","sponsor":"Kenneth Myers, MD","startDate":"2019-02-07","conditions":"Epileptic Encephalopathy, Childhood-Onset","enrollment":30},{"nctId":"NCT05102045","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-09-01","conditions":"Alzheimer Disease","enrollment":27},{"nctId":"NCT01535040","phase":"PHASE2","title":"Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2012-08-01","conditions":"Breast Cancer, Colorectal Cancer, Lung Cancer","enrollment":130},{"nctId":"NCT03565809","phase":"","title":"Quality of the Management of Diabetes in Elderly People With Dementia in France","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-02","conditions":"Alzheimer Disease","enrollment":87816},{"nctId":"NCT03221894","phase":"","title":"A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2017-07-15","conditions":"Alzheimer Disease","enrollment":120},{"nctId":"NCT05015595","phase":"PHASE3","title":"Memantine for Refractory OCD Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":20},{"nctId":"NCT00880685","phase":"PHASE2","title":"Memantine in the Treatment of Kleptomania","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-03","conditions":"Kleptomania","enrollment":12},{"nctId":"NCT02080364","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"vTv Therapeutics","startDate":"2015-04","conditions":"Alzheimer's Disease","enrollment":880},{"nctId":"NCT02811627","phase":"EARLY_PHASE1","title":"Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2016-06","conditions":"Autism Spectrum Disorder","enrollment":10},{"nctId":"NCT03988803","phase":"PHASE1","title":"A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-07-17","conditions":"Healthy","enrollment":16},{"nctId":"NCT04801342","phase":"PHASE2","title":"Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-04-01","conditions":"Metastatic Malignant Neoplasm to Brain","enrollment":72},{"nctId":"NCT01585168","phase":"PHASE2","title":"Functional Neuroimaging of Alcoholism Vulnerability (PIT)","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-12","conditions":"Healthy","enrollment":71},{"nctId":"NCT04035798","phase":"PHASE2, PHASE3","title":"add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-08-01","conditions":"Bipolar II Disorder","enrollment":120},{"nctId":"NCT04737967","phase":"PHASE2, PHASE3","title":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mendel AI","startDate":"2021-02-15","conditions":"Oncology Pain, Chemotherapy-induced Peripheral Neuropathy","enrollment":60},{"nctId":"NCT00652457","phase":"PHASE4","title":"Study of Memantine to Treat Huntington's Disease","status":"COMPLETED","sponsor":"Jody Corey-Bloom, MD, PhD","startDate":"2004-11-23","conditions":"Huntington's Disease","enrollment":50},{"nctId":"NCT04687566","phase":"PHASE2, PHASE3","title":"Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-08-11","conditions":"Amphetamine Addiction, Pharmacotherapy","enrollment":120},{"nctId":"NCT03729128","phase":"PHASE1, PHASE2","title":"Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder","status":"COMPLETED","sponsor":"Tzu-Yun Wang","startDate":"2018-07-24","conditions":"Stimulants Use Disorder","enrollment":85},{"nctId":"NCT00545974","phase":"PHASE4","title":"Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-10","conditions":"Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia","enrollment":81},{"nctId":"NCT02535611","phase":"PHASE3","title":"Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2015-10","conditions":"Ischemic Stroke, Excitotoxicity, Memantine","enrollment":47},{"nctId":"NCT03560245","phase":"PHASE2","title":"A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine","status":"COMPLETED","sponsor":"Neurotrope Bioscience, Inc.","startDate":"2018-06-20","conditions":"Alzheimer Disease","enrollment":108},{"nctId":"NCT03959124","phase":"NA","title":"Deep Brain Stimulation for Alzheimer's Disease","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-04-06","conditions":"Alzheimer Disease, Dementia, Alzheimer Type, Deep Brain Stimulation","enrollment":30},{"nctId":"NCT03858270","phase":"PHASE3","title":"Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":"Parkinson Disease","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":116,"reaction":"FALL"},{"count":82,"reaction":"CONFUSIONAL STATE"},{"count":67,"reaction":"DRUG INTERACTION"},{"count":60,"reaction":"SOMNOLENCE"},{"count":55,"reaction":"MALAISE"},{"count":40,"reaction":"ASTHENIA"},{"count":40,"reaction":"CONDITION AGGRAVATED"},{"count":40,"reaction":"VOMITING"},{"count":39,"reaction":"PYREXIA"},{"count":38,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1699"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":27,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ebixa","genericName":"Ebixa","companyName":"Konkuk University Medical Center","companyId":"konkuk-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:22.411713+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}